How State and Federal Regulations Are Reshaping Healthcare Deals with Andrew Bab

Andrew Bab, Partner & Co-Chair of the Healthcare Group at Debevoise & Plimpton LLP

In this episode of M&A Science, Andrew Bab joins Kison Patel live in New York to dive into the fast-changing legal landscape facing private equity deals in healthcare. From emerging state-level regulations and reverse CFIUS to FDA policy shifts and CVR litigation, Andrew offers a masterclass in legal diligence and deal structuring. They also explore how political scrutiny and increasing regulatory complexity are driving the need for more proactive, buyer-led approaches in healthcare M&A.

Things you will learn:

How state-level regulation is changing the game for healthcare deals
What private equity needs to know about DEI rollbacks and False Claims Act liability
Impacts of recent Delaware case law and why some firms are leaving the state
When to use CVRs in pharma M&A and the litigation risks they carry
How new HSR rules and antitrust dynamics are shifting auction timelines

Andrew Bab

Andrew Bab is a Partner at Debevoise & Plimpton and Co-Chair of the firm's Healthcare Group. With more than 35 years of experience, Andrew specializes in public and private M&A, with a deep focus on private equity and healthcare transactions. He has advised on complex regulatory issues, creative deal structures, and cutting-edge litigation in the M&A space. Andrew is widely regarded as one of the foremost legal experts in healthcare dealmaking.